Valion Bio, Inc. Common Stock (NASDAQ:VBIO) Issues Quarterly Earnings Results, Beats Expectations By $405.83 EPS

Valion Bio, Inc. Common Stock (NASDAQ:VBIO) posted its earnings results on Friday. The company reported ($2.17) earnings per share for the quarter, topping analysts’ consensus estimates of ($408.00) by $405.83, FiscalAI reports.

Valion Bio, Inc. Common Stock Stock Up 11.6%

NASDAQ:VBIO traded up $0.02 during trading hours on Friday, reaching $0.19. The company had a trading volume of 169,670,743 shares, compared to its average volume of 2,503,005. Valion Bio, Inc. Common Stock has a twelve month low of $0.16 and a twelve month high of $5.60. The company has a quick ratio of 3.02, a current ratio of 3.31 and a debt-to-equity ratio of 0.62. The firm has a market cap of $790,990.00, a price-to-earnings ratio of -0.03 and a beta of 1.85. The business’s 50-day simple moving average is $0.45 and its two-hundred day simple moving average is $0.78.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Valion Bio, Inc. Common Stock in a research note on Friday, July 17th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Valion Bio, Inc. Common Stock has a consensus rating of “Sell”.

Valion Bio, Inc. Common Stock Company Profile

Tivic Health Systems is a commercial-stage medical technology company that develops and markets non-drug, neuromodulation-based therapies for nasal and sinus health. The company’s solutions are designed to alleviate sinus pain, pressure and congestion through gentle microcurrent and vibration stimulation. By targeting the underlying nerve pathways in the nasal passages, Tivic Health aims to provide an alternative to over-the-counter and prescription medications without introducing systemic side effects.

The flagship product, ClearUP™ Sinus Pain Relief, is an FDA-cleared, hand-held device intended for home use.